• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA 0.00% 21.0¢

PHARMAUST LIMITED - Announcements

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Announcements


PAA PharmAust Canine Trial Update clarificationPRICE SENSITIVE20/12/22 download Created with Sketch. 3.29MB
PAA PharmAust Canine Trial UpdatePRICE SENSITIVE20/12/22 download Created with Sketch. 3.2MB
PAA PharmAust Receives R&D Tax Incentive RefundPRICE SENSITIVE12/12/22 download Created with Sketch. 185.99KB
PAA MND Trial Completes Enrolment of First Patient CohortPRICE SENSITIVE02/12/22 download Created with Sketch. 252.5KB
PAA Results of Annual General Meeting11/11/22 download Created with Sketch. 467.34KB
PAA AGM Presentation10/11/22 download Created with Sketch. 2.33MB
PAA Epichem webinar presentation04/11/22 download Created with Sketch. 1.21MB
PAA DNDi contract extension for PharmAust subsidiary EpichemPRICE SENSITIVE03/11/22 download Created with Sketch. 250.21KB
PAA Investor Webinar01/11/22 download Created with Sketch. 103.73KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE31/10/22 download Created with Sketch. 2.31MB
PAA First Patient Dosed in MND Phase 1/2 TrialPRICE SENSITIVE03/10/22 download Created with Sketch. 213.96KB
PAA Notice of Annual General Meeting/Proxy Form30/09/22 download Created with Sketch. 462.49KB
PAA Change of Director's Interest Notice13/09/22 download Created with Sketch. 182.88KB
PAA First Patient in US Canine Cancer Trials Begins TreatmentPRICE SENSITIVE07/09/22 download Created with Sketch. 209.08KB
PAA Appendix 4G & Corporate Governance Statement26/08/22 download Created with Sketch. 542.46KB
PAA Appendix 4E & Full Year Statutory AccountsPRICE SENSITIVE26/08/22 download Created with Sketch. 1.5MB
PAA Update on PharmAust Canine Cancer TrialsPRICE SENSITIVE17/08/22 download Created with Sketch. 375.4KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE20/07/22 download Created with Sketch. 634.05KB
PAA Notification of cessation of securities - PAA30/06/22 download Created with Sketch. 21.48KB
PAA Science Week Conference Presentation24/06/22 download Created with Sketch. 704.25KB
PAA Fiona Milner appointed Epichem General Manager30/05/22 download Created with Sketch. 201.49KB
PAA Resignation of Dr Richard Mollard27/05/22 download Created with Sketch. 204.65KB
PAA PharmAust Clinical Trials UpdatePRICE SENSITIVE24/05/22 download Created with Sketch. 221.67KB
PAA PharmAust receives $210k prepayment of forecast R&D rebatePRICE SENSITIVE17/05/22 download Created with Sketch. 188.38KB
PAA MPL tablets arrive in Melbourne for MND Clinical TrialPRICE SENSITIVE16/05/22 download Created with Sketch. 219.07KB
PAA PharmAust Expands Lymphoma Canine Trial to the USAPRICE SENSITIVE11/05/22 download Created with Sketch. 222.32KB
PAA Notification of cessation of securities - PAA29/04/22 download Created with Sketch. 22.01KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/04/22 download Created with Sketch. 860.4KB
PAA PharmAust Receives $708k R&D Tax Incentive RefundPRICE SENSITIVE19/04/22 download Created with Sketch. 187.5KB
PAA PAA appoints trial manager & receives $200k from FightMNDPRICE SENSITIVE08/04/22 download Created with Sketch. 219.61KB
PAA Notification of cessation of securities - PAA31/03/22 download Created with Sketch. 21.49KB
PAA MPL manufactured and tableting commencedPRICE SENSITIVE15/03/22 download Created with Sketch. 212.64KB
PAA Preliminary MPL antiviral leukaemia preclinical WEHI resultsPRICE SENSITIVE23/02/22 download Created with Sketch. 243.37KB
PAA Key Appointment to Progress MPL COVID-19 Clinical TrialPRICE SENSITIVE21/02/22 download Created with Sketch. 316.4KB
PAA Appendix 4D & Half Year ReportPRICE SENSITIVE18/02/22 download Created with Sketch. 1.08MB
PAA Epichem Confirms Effectiveness of OHD E-Waste ProjectPRICE SENSITIVE16/02/22 download Created with Sketch. 224KB
PAA Resignation of Epichem CEO03/02/22 download Created with Sketch. 187.14KB
PAA Update on Manufacture of MPL & Tablets for Clinical TrialsPRICE SENSITIVE02/02/22 download Created with Sketch. 202.99KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE31/01/22 download Created with Sketch. 848.78KB
PAA Epichem Awarded Contract Extension from DNDiPRICE SENSITIVE15/12/21 download Created with Sketch. 489.68KB
PAA Shareholder Update - Progress and StrategyPRICE SENSITIVE13/12/21 download Created with Sketch. 576.5KB
PAA Demonstration batch of smaller size MPL tablets completedPRICE SENSITIVE01/12/21 download Created with Sketch. 275.41KB
PAA MND & COVID-19 Phase 1 Clinical Trials On-TrackPRICE SENSITIVE17/11/21 download Created with Sketch. 218.35KB
PAA Cleansing Notice16/11/21 download Created with Sketch. 141.89KB
PAA Application for quotation of securities - PAA16/11/21 download Created with Sketch. 24.55KB
PAA Canine phase 2b cancer trial expands to New ZealandPRICE SENSITIVE15/11/21 download Created with Sketch. 234.84KB
PAA JobKeeper Payment Notification12/11/21 download Created with Sketch. 373.76KB
PAA Change of Director's Interest Notice x 409/11/21 download Created with Sketch. 250.43KB
PAA PAAO Top 20 Holders & Distribution Schedule09/11/21 download Created with Sketch. 35.01KB
PAA Application for quotation of securities - PAA09/11/21 download Created with Sketch. 24.81KB
PAA Closure of Entitlement Offer05/11/21 download Created with Sketch. 350.05KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/10/21 download Created with Sketch. 654.8KB
PAA Results of Annual General Meeting22/10/21 download Created with Sketch. 391.63KB
PAA AGM Presentation21/10/21 download Created with Sketch. 4.27MB
PAA MPL Manufacturing and Human Trials UpdatePRICE SENSITIVE21/10/21 download Created with Sketch. 223.25KB
PAA Following Extension of Survival, PAA Prepares Phase 3 TrialPRICE SENSITIVE18/10/21 download Created with Sketch. 247.8KB
PAA Proposed issue of securities - PAA01/10/21 download Created with Sketch. 30.27KB
PAA ProspectusPRICE SENSITIVE01/10/21 download Created with Sketch. 310.07KB
PAA Entitlement Options OfferPRICE SENSITIVE01/10/21 download Created with Sketch. 146.97KB
PAA Notice of Annual General Meeting/Proxy Form17/09/21 download Created with Sketch. 508.54KB
PAA Letter to shareholders re AGM17/09/21 download Created with Sketch. 76.44KB
PAA Broker Briefing Presentation Tech & Biotech Investor Webinar09/09/21 download Created with Sketch. 4.29MB
PAA Broker Briefing Investor Webinar07/09/21 download Created with Sketch. 184.35KB
PAA Epichem Completes Final Loan RepaymentPRICE SENSITIVE31/08/21 download Created with Sketch. 224.72KB
PAA Change of Director's Interest Notice24/08/21 download Created with Sketch. 181.96KB
PAA Application for quotation of securities - PAA24/08/21 download Created with Sketch. 27.06KB
PAA Appendix 4G & Corporate Governance Statement18/08/21 download Created with Sketch. 499.66KB
PAA Appendix 4E & Full Year Statutory AccountsPRICE SENSITIVE18/08/21 download Created with Sketch. 1.12MB
PAA Epichem Completes Build of OHD Benchtop Flow ReactorPRICE SENSITIVE03/08/21 download Created with Sketch. 211.58KB
PAA Virtual Investor Briefing30/07/21 download Created with Sketch. 366.64KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE28/07/21 download Created with Sketch. 522.09KB
PAA Monepantel and monepantel sulfone COVID-19 anti-viral updatePRICE SENSITIVE26/07/21 download Created with Sketch. 503.52KB
PAA PharmAust files patent for monepantel in viral diseases22/07/21 download Created with Sketch. 215.92KB
PAA PharmAust and WEHI to Investigate HTLV-1 Viral InfectionsPRICE SENSITIVE12/07/21 download Created with Sketch. 410.42KB
PAA Science Week Conference Presentation09/07/21 download Created with Sketch. 5.84MB
PAA PharmAust establishes monepantel GMP tablet stability07/07/21 download Created with Sketch. 388.35KB
PAA Phase IIb Dog Trial Achieves Interim Clinical EndpointsPRICE SENSITIVE28/06/21 download Created with Sketch. 447.83KB
PAA PharmAust receives ethics approval for Phase I trial in MNDPRICE SENSITIVE02/06/21 download Created with Sketch. 272.66KB
PAA Dr Kim Agnew appointed Principal Investigator of dog trial14/05/21 download Created with Sketch. 369.97KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE29/04/21 download Created with Sketch. 305.76KB
PAA Phase IIb Canine Trial Identifies Therapeutic Window for MPLPRICE SENSITIVE27/04/21 download Created with Sketch. 367.01KB
PAA Epichem OHD Presentation - Waste to Fuels Technology21/04/21 download Created with Sketch. 3.34MB
PAA PharmAust Receives $750k R&D Tax Incentive RefundPRICE SENSITIVE08/04/21 download Created with Sketch. 348.54KB
PAA Leiden Testing Indicates MPL SARS-CoV-2 Antiviral ActivityPRICE SENSITIVE07/04/21 download Created with Sketch. 531.65KB
PAA Trading HaltPRICE SENSITIVE06/04/21 download Created with Sketch. 412.74KB
PAA Pause in TradingPRICE SENSITIVE06/04/21 download Created with Sketch. 116.36KB
PAA Update on Phase IIb Clinical Trial of Monepantel in Pet DogsPRICE SENSITIVE30/03/21 download Created with Sketch. 392.54KB
PAA Epichem business support program for advanced technologies29/03/21 download Created with Sketch. 389.98KB
PAA Licensing Agreement to Develop Waste to Fuels TechnologyPRICE SENSITIVE23/03/21 download Created with Sketch. 324.8KB
PAA Appendix 4D & Half Year ReportPRICE SENSITIVE26/02/21 download Created with Sketch. 523.81KB
PAA Update on Phase IIb Clinical Trial recruitmentPRICE SENSITIVE15/02/21 download Created with Sketch. 346.6KB
PAA Update on COVID-19 testing in the Netherlands10/02/21 download Created with Sketch. 346.72KB
PAA Virtual Investor Briefing05/02/21 download Created with Sketch. 347.42KB
PAA Appendix 4C and Quarterly UpdatePRICE SENSITIVE27/01/21 download Created with Sketch. 490.75KB
PAA Epichem Awarded $200K WasteSorted e-Waste GrantPRICE SENSITIVE22/01/21 download Created with Sketch. 389.54KB
PAA Leiden University Medical Centre Monepantel COVID-19 TestingPRICE SENSITIVE08/01/21 download Created with Sketch. 408.85KB
PAA PAA & ONJCRI to Continue MPL Pre-clinical InvestigationsPRICE SENSITIVE05/01/21 download Created with Sketch. 400.86KB
PAA Appendix 2A & s708 notice04/01/21 download Created with Sketch. 502.57KB
PAA PAA Commences Manufacture of GMP-Grade MPL for Human TrialsPRICE SENSITIVE23/12/20 download Created with Sketch. 388.13KB
PAA PharmAust to Commence Phase IIb Dog Cancer TrialPRICE SENSITIVE22/12/20 download Created with Sketch. 369.9KB
PAA PharmAust Canine Trial Update clarification
20/12/22PRICE SENSITIVE download Created with Sketch. 3.29MB
PAA PharmAust Canine Trial Update
20/12/22PRICE SENSITIVE download Created with Sketch. 3.2MB
PAA PharmAust Receives R&D Tax Incentive Refund
12/12/22PRICE SENSITIVE download Created with Sketch. 185.99KB
PAA MND Trial Completes Enrolment of First Patient Cohort
02/12/22PRICE SENSITIVE download Created with Sketch. 252.5KB
PAA Results of Annual General Meeting
11/11/22 download Created with Sketch. 467.34KB
PAA AGM Presentation
10/11/22 download Created with Sketch. 2.33MB
PAA Epichem webinar presentation
04/11/22 download Created with Sketch. 1.21MB
PAA DNDi contract extension for PharmAust subsidiary Epichem
03/11/22PRICE SENSITIVE download Created with Sketch. 250.21KB
PAA Investor Webinar
01/11/22 download Created with Sketch. 103.73KB
PAA Appendix 4C and Quarterly Update
31/10/22PRICE SENSITIVE download Created with Sketch. 2.31MB
PAA First Patient Dosed in MND Phase 1/2 Trial
03/10/22PRICE SENSITIVE download Created with Sketch. 213.96KB
PAA Notice of Annual General Meeting/Proxy Form
30/09/22 download Created with Sketch. 462.49KB
PAA Change of Director's Interest Notice
13/09/22 download Created with Sketch. 182.88KB
PAA First Patient in US Canine Cancer Trials Begins Treatment
07/09/22PRICE SENSITIVE download Created with Sketch. 209.08KB
PAA Appendix 4G & Corporate Governance Statement
26/08/22 download Created with Sketch. 542.46KB
PAA Appendix 4E & Full Year Statutory Accounts
26/08/22PRICE SENSITIVE download Created with Sketch. 1.5MB
PAA Update on PharmAust Canine Cancer Trials
17/08/22PRICE SENSITIVE download Created with Sketch. 375.4KB
PAA Appendix 4C and Quarterly Update
20/07/22PRICE SENSITIVE download Created with Sketch. 634.05KB
PAA Notification of cessation of securities - PAA
30/06/22 download Created with Sketch. 21.48KB
PAA Science Week Conference Presentation
24/06/22 download Created with Sketch. 704.25KB
PAA Fiona Milner appointed Epichem General Manager
30/05/22 download Created with Sketch. 201.49KB
PAA Resignation of Dr Richard Mollard
27/05/22 download Created with Sketch. 204.65KB
PAA PharmAust Clinical Trials Update
24/05/22PRICE SENSITIVE download Created with Sketch. 221.67KB
PAA PharmAust receives $210k prepayment of forecast R&D rebate
17/05/22PRICE SENSITIVE download Created with Sketch. 188.38KB
PAA MPL tablets arrive in Melbourne for MND Clinical Trial
16/05/22PRICE SENSITIVE download Created with Sketch. 219.07KB
PAA PharmAust Expands Lymphoma Canine Trial to the USA
11/05/22PRICE SENSITIVE download Created with Sketch. 222.32KB
PAA Notification of cessation of securities - PAA
29/04/22 download Created with Sketch. 22.01KB
PAA Appendix 4C and Quarterly Update
29/04/22PRICE SENSITIVE download Created with Sketch. 860.4KB
PAA PharmAust Receives $708k R&D Tax Incentive Refund
19/04/22PRICE SENSITIVE download Created with Sketch. 187.5KB
PAA PAA appoints trial manager & receives $200k from FightMND
08/04/22PRICE SENSITIVE download Created with Sketch. 219.61KB
PAA Notification of cessation of securities - PAA
31/03/22 download Created with Sketch. 21.49KB
PAA MPL manufactured and tableting commenced
15/03/22PRICE SENSITIVE download Created with Sketch. 212.64KB
PAA Preliminary MPL antiviral leukaemia preclinical WEHI results
23/02/22PRICE SENSITIVE download Created with Sketch. 243.37KB
PAA Key Appointment to Progress MPL COVID-19 Clinical Trial
21/02/22PRICE SENSITIVE download Created with Sketch. 316.4KB
PAA Appendix 4D & Half Year Report
18/02/22PRICE SENSITIVE download Created with Sketch. 1.08MB
PAA Epichem Confirms Effectiveness of OHD E-Waste Project
16/02/22PRICE SENSITIVE download Created with Sketch. 224KB
PAA Resignation of Epichem CEO
03/02/22 download Created with Sketch. 187.14KB
PAA Update on Manufacture of MPL & Tablets for Clinical Trials
02/02/22PRICE SENSITIVE download Created with Sketch. 202.99KB
PAA Appendix 4C and Quarterly Update
31/01/22PRICE SENSITIVE download Created with Sketch. 848.78KB
PAA Epichem Awarded Contract Extension from DNDi
15/12/21PRICE SENSITIVE download Created with Sketch. 489.68KB
PAA Shareholder Update - Progress and Strategy
13/12/21PRICE SENSITIVE download Created with Sketch. 576.5KB
PAA Demonstration batch of smaller size MPL tablets completed
01/12/21PRICE SENSITIVE download Created with Sketch. 275.41KB
PAA MND & COVID-19 Phase 1 Clinical Trials On-Track
17/11/21PRICE SENSITIVE download Created with Sketch. 218.35KB
PAA Cleansing Notice
16/11/21 download Created with Sketch. 141.89KB
PAA Application for quotation of securities - PAA
16/11/21 download Created with Sketch. 24.55KB
PAA Canine phase 2b cancer trial expands to New Zealand
15/11/21PRICE SENSITIVE download Created with Sketch. 234.84KB
PAA JobKeeper Payment Notification
12/11/21 download Created with Sketch. 373.76KB
PAA Change of Director's Interest Notice x 4
09/11/21 download Created with Sketch. 250.43KB
PAA PAAO Top 20 Holders & Distribution Schedule
09/11/21 download Created with Sketch. 35.01KB
PAA Application for quotation of securities - PAA
09/11/21 download Created with Sketch. 24.81KB
PAA Closure of Entitlement Offer
05/11/21 download Created with Sketch. 350.05KB
PAA Appendix 4C and Quarterly Update
29/10/21PRICE SENSITIVE download Created with Sketch. 654.8KB
PAA Results of Annual General Meeting
22/10/21 download Created with Sketch. 391.63KB
PAA AGM Presentation
21/10/21 download Created with Sketch. 4.27MB
PAA MPL Manufacturing and Human Trials Update
21/10/21PRICE SENSITIVE download Created with Sketch. 223.25KB
PAA Following Extension of Survival, PAA Prepares Phase 3 Trial
18/10/21PRICE SENSITIVE download Created with Sketch. 247.8KB
PAA Proposed issue of securities - PAA
01/10/21 download Created with Sketch. 30.27KB
PAA Prospectus
01/10/21PRICE SENSITIVE download Created with Sketch. 310.07KB
PAA Entitlement Options Offer
01/10/21PRICE SENSITIVE download Created with Sketch. 146.97KB
PAA Notice of Annual General Meeting/Proxy Form
17/09/21 download Created with Sketch. 508.54KB
PAA Letter to shareholders re AGM
17/09/21 download Created with Sketch. 76.44KB
PAA Broker Briefing Presentation Tech & Biotech Investor Webinar
09/09/21 download Created with Sketch. 4.29MB
PAA Broker Briefing Investor Webinar
07/09/21 download Created with Sketch. 184.35KB
PAA Epichem Completes Final Loan Repayment
31/08/21PRICE SENSITIVE download Created with Sketch. 224.72KB
PAA Change of Director's Interest Notice
24/08/21 download Created with Sketch. 181.96KB
PAA Application for quotation of securities - PAA
24/08/21 download Created with Sketch. 27.06KB
PAA Appendix 4G & Corporate Governance Statement
18/08/21 download Created with Sketch. 499.66KB
PAA Appendix 4E & Full Year Statutory Accounts
18/08/21PRICE SENSITIVE download Created with Sketch. 1.12MB
PAA Epichem Completes Build of OHD Benchtop Flow Reactor
03/08/21PRICE SENSITIVE download Created with Sketch. 211.58KB
PAA Virtual Investor Briefing
30/07/21 download Created with Sketch. 366.64KB
PAA Appendix 4C and Quarterly Update
28/07/21PRICE SENSITIVE download Created with Sketch. 522.09KB
PAA Monepantel and monepantel sulfone COVID-19 anti-viral update
26/07/21PRICE SENSITIVE download Created with Sketch. 503.52KB
PAA PharmAust files patent for monepantel in viral diseases
22/07/21 download Created with Sketch. 215.92KB
PAA PharmAust and WEHI to Investigate HTLV-1 Viral Infections
12/07/21PRICE SENSITIVE download Created with Sketch. 410.42KB
PAA Science Week Conference Presentation
09/07/21 download Created with Sketch. 5.84MB
PAA PharmAust establishes monepantel GMP tablet stability
07/07/21 download Created with Sketch. 388.35KB
PAA Phase IIb Dog Trial Achieves Interim Clinical Endpoints
28/06/21PRICE SENSITIVE download Created with Sketch. 447.83KB
PAA PharmAust receives ethics approval for Phase I trial in MND
02/06/21PRICE SENSITIVE download Created with Sketch. 272.66KB
PAA Dr Kim Agnew appointed Principal Investigator of dog trial
14/05/21 download Created with Sketch. 369.97KB
PAA Appendix 4C and Quarterly Update
29/04/21PRICE SENSITIVE download Created with Sketch. 305.76KB
PAA Phase IIb Canine Trial Identifies Therapeutic Window for MPL
27/04/21PRICE SENSITIVE download Created with Sketch. 367.01KB
PAA Epichem OHD Presentation - Waste to Fuels Technology
21/04/21 download Created with Sketch. 3.34MB
PAA PharmAust Receives $750k R&D Tax Incentive Refund
08/04/21PRICE SENSITIVE download Created with Sketch. 348.54KB
PAA Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
07/04/21PRICE SENSITIVE download Created with Sketch. 531.65KB
PAA Trading Halt
06/04/21PRICE SENSITIVE download Created with Sketch. 412.74KB
PAA Pause in Trading
06/04/21PRICE SENSITIVE download Created with Sketch. 116.36KB
PAA Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
30/03/21PRICE SENSITIVE download Created with Sketch. 392.54KB
PAA Epichem business support program for advanced technologies
29/03/21 download Created with Sketch. 389.98KB
PAA Licensing Agreement to Develop Waste to Fuels Technology
23/03/21PRICE SENSITIVE download Created with Sketch. 324.8KB
PAA Appendix 4D & Half Year Report
26/02/21PRICE SENSITIVE download Created with Sketch. 523.81KB
PAA Update on Phase IIb Clinical Trial recruitment
15/02/21PRICE SENSITIVE download Created with Sketch. 346.6KB
PAA Update on COVID-19 testing in the Netherlands
10/02/21 download Created with Sketch. 346.72KB
PAA Virtual Investor Briefing
05/02/21 download Created with Sketch. 347.42KB
PAA Appendix 4C and Quarterly Update
27/01/21PRICE SENSITIVE download Created with Sketch. 490.75KB
PAA Epichem Awarded $200K WasteSorted e-Waste Grant
22/01/21PRICE SENSITIVE download Created with Sketch. 389.54KB
PAA Leiden University Medical Centre Monepantel COVID-19 Testing
08/01/21PRICE SENSITIVE download Created with Sketch. 408.85KB
PAA PAA & ONJCRI to Continue MPL Pre-clinical Investigations
05/01/21PRICE SENSITIVE download Created with Sketch. 400.86KB
PAA Appendix 2A & s708 notice
04/01/21 download Created with Sketch. 502.57KB
PAA PAA Commences Manufacture of GMP-Grade MPL for Human Trials
23/12/20PRICE SENSITIVE download Created with Sketch. 388.13KB
PAA PharmAust to Commence Phase IIb Dog Cancer Trial
22/12/20PRICE SENSITIVE download Created with Sketch. 369.9KB
(20min delay)
Last
21.0¢
Change
0.000(0.00%)
Mkt cap ! $93.45M
Open High Low Value Volume
21.0¢ 21.5¢ 20.5¢ $106.7K 516.1K

Buyers (Bids)

No. Vol. Price($)
2 24033 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 55077 2
View Market Depth
Last trade - 15.22pm 22/07/2024 (20 minute delay) ?
Last
21.0¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
21.0¢ 21.0¢ 20.5¢ 342599
Last updated 15.22pm 22/07/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.